Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer

Transl Cancer Res. 2023 Mar 31;12(3):456-460. doi: 10.21037/tcr-22-2888. Epub 2023 Mar 14.

Authors

Rafael Rosell^{1

2

3}, María González-Cao³, Jordi Codony-Servat⁴, Miguel Angel Molina-Vila⁴, Clara Mayo de Las Casas⁴, Masaoki Ito⁵

Affiliations

¹ Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
² Catalan Institute of Oncology (ICO), Badalona, Spain.
³ Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Hospital, Barcelona, Spain.
⁴ Laboratory of Oncology, Pangaea Oncology, Quirón-Dexeus University Hospital, Barcelona, Spain.
⁵ Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

No abstract available

Keywords: BRAF; RAF; ROS1; missense mutations; mitogen-activated protein kinase (MAPK).

Publication types

Editorial
Comment